FDA Potency Assurance guidance: where it sits in the product lifecycle
FDA press announcement, 2 November 2026. Final guidance replaces the 2011 potency testing guidance.
Lifecycle
Early development, IND, BLA and post-market
FDA recommendation: build potency assurance through the whole lifecycle
What it covers
Raw material variability, in-process testing, and batch activity that matches intended effect
Also covers viral vector products, short-shelf-life products and patient-specific therapies
Webinar
10 December 2026
This is guidance, not a binding rule. The statutory verification duty is described from approval through post-approval monitoring.
As described in FDA's 2 November 2026 announcement. This graphic is based on the press announcement, not a line-by-line reading of the guidance text.
Potency is now a lifecycle plan.
The 2011 guidance is replaced.
On 2 November FDA issued final guidance recommending a science and risk based Potency Assurance Strategy for cellular and gene therapies (FDA announcement). It replaces the 2011 potency testing guidance.
What was reported
The final guidance is titled Potency Assurance for Cellular and Gene Therapy Products. FDA says it guides manufacturers to verify, before a product reaches a patient, that every batch meets a defined potency standard. It replaces the 2011 potency testing guidance.
FDA describes flexible, risk based recommendations that integrate potency considerations at every stage. These run from early-phase IND submissions through BLA approval and continued post-market verification.
Key topics named in the announcement are raw material variability controls and testing during manufacturing. They also include lab tests confirming each batch is biologically active in a way that matches its intended therapeutic effect.
The guidance also addresses specialized considerations for products with short shelf lives, viral vector gene therapies and patient-specific therapies. FDA will host a webinar on 10 December 2026.
What this does and does not show
This note rests on FDA's press announcement, not on a full reading of the guidance text. We cannot say here which assays, matrix designs or timelines the guidance recommends for AAV products.
FDA says the statutory expectation is that manufacturers verify their products work as intended, from approval through post-approval monitoring. The guidance gives current thinking on how to meet it.
It does not tell a specific sponsor what its own assay package should look like. That judgement still depends on the product, its mechanism and its stage.
What GTC would ask
In our view, the avoidable hurdle for AAV developers is treating potency as a late release test. Ask whether the potency assay rationale was written alongside early manufacturing decisions, or added once the process was fixed.
Ask whether the assay measures biological activity in a way that matches the product's intended therapeutic effect, as the announcement frames it. Ask also where raw material variability and in-process testing enter the control strategy.
For investors: ask whether the CDMO and the sponsor agree who owns assay development, and whether the plan changes between IND and BLA stages.
Practical takeaway
Check that the potency assay, the manufacturing controls and the intended therapeutic activity tell one consistent story. Then read the full guidance against your current plan before the 10 December webinar, and log each gap as a dated action.
Related GTC reading
Frequently asked questions
What did FDA announce on 2 November 2026?
FDA issued final guidance, Potency Assurance for Cellular and Gene Therapy Products, recommending a science and risk based Potency Assurance Strategy. It replaces FDA's 2011 potency testing guidance.
Which stages of development does the guidance cover?
According to FDA's announcement, it covers early-phase IND submissions through BLA approval and continued post-market verification. FDA describes the recommendations as flexible and risk based.
Does the guidance address viral vector gene therapies?
Yes. FDA says it addresses specialized considerations for viral vector gene therapies, as well as products with short shelf lives and patient-specific therapies.
What topics does the announcement highlight?
FDA highlights controls for raw material variability, testing during manufacturing, and lab tests confirming each batch is biologically active in a way that matches its intended therapeutic effect.
Is there a webinar on the guidance?
Yes. FDA says it will host a webinar on 10 December 2026 to help stakeholders understand and implement the guidance.
Sources
- FDA, FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality, 2 November 2026 - 2026-11-02
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.